|
Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes
|
Jan 2017
|
Ther Adv Hematol
|
myelodysplastic syndromes (MDS)
|
|
Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician's guide
|
Mar 2017
|
Ther Adv Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes
|
Apr 2023
|
The Oncologist
|
myelodysplastic syndromes (MDS)
|
|
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes
|
Apr 2023
|
The Oncologist
|
myelodysplastic syndromes (MDS)
|
|
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|
Mar 2021
|
The New England Journal of Medicine
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
|
Jan 2020
|
The New England Journal of Medicine
|
myelodysplastic syndromes (MDS)
|
|
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
|
Jun 2019
|
The Lancet Haematology
|
myelodysplastic syndromes (MDS)
|
|
Paroxysmal nocturnal hemoglobinuria without GPI-anchor deficiency
|
Oct 2019
|
The Journal of Clinical Investigation
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Epidemiology and Pathogenesis of Myelodysplastic Syndrome
|
May 2023
|
The Cancer Journal
|
myelodysplastic syndromes (MDS)
|
|
Overview of the Management of Higher-Risk Myelodysplastic Syndromes
|
May 2023
|
The Cancer Journal
|
myelodysplastic syndromes (MDS)
|
